Skip to main content

Fiscal Wizard · Single-issue tearsheet

MESO / Jun 22, 2026 Run #7632

MESO

Mesoblast Limited

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Composite verdict

F 18.2 / 100
Bearish setup · Trend Following 12 drivers · 4 gates blocking
  • Double 7s
  • Chaikin Money Flow
  • Connors RSI(2)
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 300th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 17 signals100% Bear
Momentum Bearish 12Mean-reversion Bearish 39

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -77%

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

36.5 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Return on Capital Employed 79
Margin of Safety 0
Return on Assets 78
Free Cash Flow Yield 0
Greenblatt EY 75
Inventory Turnover 0

Technicals Bearish

0.0 / 100

Bearish setup leads (Double 7s, Chaikin Money Flow, Connors RSI(2)); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Chaikin Money Flow 11
Double 7s 11
Connors RSI(2) 12

Risk Gates

4 blocking 1 caution

4 guards active, 23 signals gated.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for MESO.